Heart failure in women

Current Cardiology Reports

Volumn 7, Issue 3, 2005, Pages 159-165

  Barnard, Denise D ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMIODARONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; ESTROGEN; HYDRALAZINE; NEUROHORMONE; NITRATE; PLACEBO; RAMIPRIL; RENIN; SPIRONOLACTONE; TRANDOLAPRIL;

AWARENESS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DATA ANALYSIS; DEFIBRILLATOR; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LETHALITY; LIFESPAN; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL; TREATMENT PLANNING;

EID: 23844473749     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-005-0071-x     Document Type: Review

References (50)

1. Heart Disease and Stroke Statistics - 2005 Update. American Heart Association. http://www.americanheart.org/presenter.jhtml?identifier=3000090
2. Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: the Framingham study. Circulation 2002, 106:3068-3072.
3. Centers for Disease Control and Prevention: 2002 National Health Care Statistics. http://www.cdc.gov/nchs/data/hus/hus02.pdf
4. Lund LH, Mancini D: Heart failure in women. Med Clin North Am 2004, 88:321-345.
5. Petrie MC, Dawson NF, Murdoch DR, et al.: Failure of women's hearts. Circulation 1999, 99:2334-2341.
6. Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
7. Chobanian AV, Bakris GL, Black HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC-7 report. JAMA 2003, 289:2560-2573.
8. Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993, 22:6A-13A.
9. Senni M, Tribouilloy CM, Rodeheffer RJ, et al.: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999, 159:29-34.
10. Redfield MM, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community. Appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
11. Hermann DD, Hoppe BL: Gender differences in the causes and natural history of heart failure. Curr Cardiology Rep 2003, 5:193-199.
12. Yusuf S, Pfeffer MA, Svedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
13. Johnstone D, Limacher M, Rousseau M, et al.: Clinical characteristics of patients in the Studies of Left Ventricular Dysfunction. Am J Cardiol 1992, 70:894-900.
14. American Medical Association. Report 4 of the Council on Scientific Affairs. Presented at the 2000 AMA Interim Meeting. Orlando, FL; December 3-6, 2000.
15. Topol E, Traill T, Fortuin N: Hypertensive hypertrophy cardiomyopathy of the elderly. N Engl J Med 1985, 312:277-283.
16. Galderisi M, Anderson KM, Wilson PW, Levy D: Echocardiographic evidence for the exsistence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991, 68:85-89.
17. Kannel WB: Epidemiology aspects of heart failure. Cardiol Clin 1989, 7:1-9.
18. Fimmelstiel C, Goldberg RJ: Congestive heart failure in women: focus on heart failure die to coronary artery disease and diabetes. Cardiology 1990, 77(Suppl 2):71-79.
19. Hoffman RM, Pstay BM, Kronal RA: Modifiable risk factors for the incident heart failure in the Coronary Artery Surgery Study. Arch Inter Med 1994, 154:417-423.
20. Bibbins-Domingo K, Lin F, Vittinghoff E, et al.: Predictors of heart failure among women with coronary disease. Circulation 2004, 100:1424-1430.
21. Hunt SA, Baker DW, Chin MH, et al.: Evaluation and management of heart failure. ACC/AHA practice guidelines for evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001, 38:2101-2113.
22. Burke GL, Bell RA: Global trends in cardiovascular disease: incidence and risk factors. In Preventive Cardiology: A Practical Approach. Edited by Wong ND. New York: McGraw-Hill; 2005:22-42.
23. Philbin EF, DiSalvo TG: Influence of race and gender on care process, resource use, and outcomes in congestive heart failure. Am J Cardiol 1998, 82:76-81.
24. Heiat A, Gross CP, Krumholz HM: Representation of the elderly, women and minorities in heart failure clinical trials. Arch Inter Med 2002, 162:1682-1688.
25. Tandon S, Hankins SR, LeJemtel TH: Clinical profile of chronic heart failure in elderly women. Am J Geriatr Cardio 2002, 11:318-323.
26. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995, 26:1565-1574.
27. He J, Ogden LG, Bazzano LA, et al.: Risk factors for congestive heart failure in US men and women. Arch Intern Med 2001, 161:996-1002.
28. De Maria R, Gavazzi A, Recalcati F, et al., for the Italian Multicenter Cardiomyopathy Study Group: Comparison of clinical findings in idiopathic dilated cardiomyopathy in women versus men. Am J Cardiol 1993, 72:580-585.
29. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
30. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
31. Mendes LA, Davidoff R, Cupples LA, et al.: Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997, 134:207-212.
32. Carroll JD, Carroll EP, Feldman T: Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992, 86:1099-1107.
33. Crabbe DL, Dipla K, Ambati S, et al.: Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol 2003, 41:300-306.
34. Babiker FA, Windt LJ, van Eickels M, et al.: Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 2002, 53:709-719.
35. Light KC, Hinderliter AL, West SG, et al.: Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive post-menopausal patients. J Hypertens 2001, 2:269-278.
36. Fischer M, Baessler A, Schunkert H: Renin-angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002, 53:672-677.
37. Douglas PS, Katz SE, Weinberg EO: Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998, 32:1118-1125.
38. Feldmer M, Kaling M, Takahashi S, et al.: Glucocorticoid and estrogen-responsive elements in the 5′ flanking region of the rat angiotensinogen gene. J Hypertens 1991, 9:1005-1012.
39. Clauser E, Gaillard I, Wei L, Corvol P: Regulation of angiotensinogen gene. Am J Hypertens 1989, 2:403-410.
40. The CONSENSUS Trial Group: Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429-1435.
41. The Trandolapril Cardiac Evaluation (TRACE) Group: A clinical trial of the angiotensinogen converting enzyme trandolapril inpatients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670-1676.
42. Ambrosioni E, Borghi C, Magnani B: The effect of angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995, 332:80-85.
43. The SAVE Investigators: Effect of mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992, 327:669-677.
44. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
45. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
46. Chali JK, Pina IL, Gottlieb SS, et al., for the MERIT-HF Study Group: Metoprolol CR/XL in female patients with heart failure. Analysis of the experiences in Metoprolol Extended-release Randomization Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002, 105:1585-1591.
47. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
48. Rathore SS, Wang Y, Krumholz HM: Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403-1411.
49. Pires LA, Sethuraman B, Guduguntla VD, et al.: Outcome of women versus men with ventricular tachyarrhythmias treated with the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2002, 13:563-568.
50. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 343:475-480.